Pharmacotherapies for Drug-Induced Liver Injury: A Current Literature Review

Meng Li; Qiong Luo; Yanyan Tao; Xin Sun; Chenghai Liu

doi:10.3389/fphar.2021.806249

Pharmacotherapies for Drug-Induced Liver Injury: A Current Literature Review

Front Pharmacol. 2022 Jan 5:12:806249. doi: 10.3389/fphar.2021.806249. eCollection 2021.

Authors

Meng Li¹, Qiong Luo¹, Yanyan Tao¹, Xin Sun^{1

2}, Chenghai Liu^{1

2

3

4}

Affiliations

¹ Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
² Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Shanghai, China.
³ Key Laboratory of Liver and Kidney Diseases, Ministry of Education, Shanghai, China.
⁴ Shanghai Innovation Center of TCM Health Service, Shanghai, China.

Abstract

Drug-induced liver injury (DILI) has become a serious public health problem. For the management of DILI, discontinuation of suspicious drug or medicine is the first step, but the treatments including drugs and supporting approaches are needed. Reference to clinical patterns and disease severity grades of DILI, the treatment drugs were considered to summarize into hepatoprotective drugs (N-acetylcysteine and Glutathione, Glycyrrhizin acid preparation, Polyene phosphatidylcholine, Bicyclol, Silymarin), anticholestatic drug (Ursodeoxycholic acid, S-adenosylmethionine, Cholestyramine), immunosuppressants (Glucocorticoids) and specific treatment agents (L-carnitine, Anticoagulants). The current article reviewed the accumulated literature with evidence-based medicine researches for DILI in clinical practice. Also the drawbacks of the clinical studies involved in the article, unmet needs and prospective development for DILI therapy were discussed.

Keywords: acute liver failure; anticholestatic drug; drug-induced liver injury; hepatoprotective drug; pharmacotherapy.

Publication types

Review